Antiarrhythmic β-blockers are used in patients at risk of myocardial ischaemia, but the survival benefit and mechanisms are unclear. We hypothesized that β-blockers do not prevent ventricular fibrillation (VF) but instead inhibit the ability of catecholamines to facilitate ischaemia-induced VF, limiting the scope of their usefulness.
Introduction
Sudden cardiac death (SCD) contributes >60% of cardiovascular disease-related deaths, with a majority of these due to ventricular fibrillation (VF) caused by acute myocardial ischaemia, and the search for targetable mechanisms has proven challenging (Adabag et al., 2010; John et al., 2012) .
During the first 30 min of ischaemia (the 'phase 1' period), VF risk is intrinsically proportional to the severity of ischaemia, which is determined primarily by ischaemic zone (IZ) size, set by occlusion location, and by collateral flow (Curtis, 1998; . Separately, VF risk can be modulated by extrinsic factors such as heart rate (HR) and blood-born factors . The relationships between VF incidence and IZ size, and other independent variables, are well characterized in the rat Langendorff preparation, rendering it a tractable assay system (Curtis, 1998) .
Catecholamines have long been regarded as mediators of ischaemia-induced VF with myocardial β 1 -adrenoceptor agonism the most plausible mechanism; however, there are inconsistencies in the published literature with regard to the relationship between the absolute levels of catecholamines accumulating in the ischaemic territory and the incidence of ischaemia-induced ventricular arrhythmias (see discussion for further analysis) . Thus, in animals, ischaemia causes catecholamine accumulation in the IZ (Lameris et al., 2000; Schömig et al., 1984) , yet the timing does not accord with the timing of VF onset (Curtis, 1998) . Adrenoceptor antagonists inhibit ischaemiainduced VF, yet doses/concentrations tested often lack selectivity for their intended target adrenoceptor, and effects (e.g. a reduction in ischaemia-induced VF incidence) are better explained by non-specific and even extra-cardiac, off-target effects, as suggested by others (Daugherty et al., 1986; Tölg et al., 1997) . Some effects are model-dependent, for example, off-target β 2 -adrenoceptor antagonist actions in acutely prepared animals (e.g. rat) elevate circulating blood potassium concentrations resulting in VF suppression, an artefact that does not occur in conscious animals subjected to regional ischaemia when fully recovered from preparative surgery (Botting et al., 1983; Paletta et al., 1989) or indeed in isolated hearts where, due to delivery of Krebs directly to the coronary vasculature and an absence of a circulation, the scope for an alteration in circulating blood potassium is zero. In patients with previous ventricular tachycardia (VT) or VF, and acute myocardial infarction (MI), plasma catecholamines can become elevated (Meredith et al., 1991; Slavikova et al., 2007) . β adrenoceptor antagonists reduce mortality in such patients, but only moderately (Nademanee et al., 2000; β-Blocker Heart Attack Study Group, 1981) , and their specific effects on VF remain unclear, despite decades of use (ISIS-1 Collaborative Group, 1988; The MIAMI Trial Research Group, 1985) .
It is important to clarify whether catecholamines are important therapeutic targets for VF suppression or not. It may be possible to reconcile published data if it were the case that catecholamines facilitate phase 1 ischaemia-induced VF rather than mediate it. The corollary of this novel hypothesis is that the relevance of catecholamines will depend on the influence of other factors such as IZ size. Here, we found that catecholamines acting primarily in the non-ischaemic uninvolved zone (UZ) facilitated ischaemia-induced VF in rat isolated hearts, but only when IZ was small (rendering VF risk low). The mechanism, identified using selective and specific adrenoceptor antagonists and confirmatory immunoblotting, required dual agonism of β 1 -and β 2 -adrenoceptors. These data explain the likely role of catecholamines in SCD/VF and receptor mechanism, and the limits of achievable protection from adrenoceptor antagonists.
Methods

Ethical statement
Experiments were approved by the King's College London ethics review board and performed in accordance with the guidelines from Directive 2010/63/EU of the European Parliament on the protection of animals used for scientific purposes, the United Kingdom Home office Guide on the Operation of the Animals (Scientific Procedures) Act 1986 and recent guidelines on experimental design and analysis (Curtis et al., 2015) . Animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny et al., 2010; McGrath and Lilley, 2015) . Animal housing and husbandry were exactly as described previously (Andrag and Curtis, 2013) , and all test solutions and data analysis were blinded by way of coding. To blind the study, the operator gave a second person a book that listed the groups to be studied. The second person wrote a code by the name of each group (e.g. Brighton, Palace and ManU) and relabelled the stock bottles (identical) with the name of the experimental group. The operator then aliquoted the coded stocks, and the code book was kept by the second person until the experiment was completed and analysed. A total of 620 animals were randomized to groups.
Animals, general experimental methods and experimental strategy
Male Wistar rats (Harlan UK; 220-410 g) were anaesthetized by i.p. injection of a lethal dose of sodium pentobarbitone (170 mg·kg À1 ) and co-administered sodium heparin (160 IU·kg À1 ) (Wilder et al., 2016) . A surgical level of anaesthesia was determined by the absence of pedal and corneal reflexes, prior to cardiac excision and exsanguination. Hearts were immediately removed and arrested in ice-cold modified Krebs control solution (hereafter called 'Krebs'), containing NaCl 118.5 mM, CaCl2 1.4 mM, glucose 11.1 mM, NaHCO3 25.0 mM, MgSO4 1.2 mM, NaH2PO4 1.2 mM and KCl 3 mM, then mounted on to a metal cannula via the aorta for Langendorff perfusion with gassed and warmed (95% O 2 : 5% CO 2 ; pH 7.4; 37°C) Krebs. All perfusion solutions were filtered (5 μm pore size) before use and delivered at a constant pressure of approximately 80 mmHg (generated by the height of the perfusion columns). A unipolar ECG recording was used for assessment of cardiac rhythm by inserting a wire electrode into the left ventricular wall at the apex of the heart, as described previously (Dhanjal et al., 2013) , and ventricular arrhythmias ( Figure 1 ) were identified using the Lambeth Conventions II definitions . To obtain coronary occlusion, a silk suture sewn under the left main coronary artery was threaded through a polythene tube, which was tightened and clamped using curved Spencer Wells forceps to induce regional ischaemia, and later loosened to achieve reperfusion (normally 30 min after the onset of ischaemia). To generate an IZ of specific size, a silk suture was placed loosely around the left main coronary artery at one of three predetermined set levels: distal, medial or proximal to the atrial appendage, generating a small, medium or large IZ respectively (Table 1) (Andrag and Curtis, 2013; .
After reperfusion, the IZ was identified by perfusing hearts with disulphine blue dye (Patent blue VF sodium salt, Sigma Aldrich®, UK), followed by re-occlusion of the left main coronary artery. Hearts were then perfused with dye-free test solution in order to wash out any excess blue dye from the UZ. The IZ and UZ were dissected and weighed, and the IZ was quantified as a percentage of total ventricular weight (TVW). In hearts in which reperfusion was not possible because IZs and UZs were required for immunoblotting (catecholamines + antagonist study), the IZ was judged from the location of the occluder and downstream tissue discolouration and dissected by eye, with values verified by % reduction in coronary flow following coronary ligation (Curtis, 1998) .
The need to generate groups of different IZ sizes is an intrinsic aspect of our experimental strategy and is predicated by the hypothesis that catecholamines facilitate ischaemiainduced VF, and this is feasible only when VF risk is low, meaning that there exists scope for the incidence of VF in a group of hearts to be increased. When IZ is large (Table 1) , it is well established that in a group of rat isolated hearts, the incidence of ischaemia-induced VF will be high, meaning that the scope for facilitation of VF will be too low for facilitation to be pathophysiologically relevant, or indeed detectable by statistical analysis in a typical study of no more than n = 20 hearts per group (Curtis, 1998) . In addition to statistical considerations, evaluating possible facilitation of VF in hearts with smaller IZ sizes makes biological sense since it is known that numerous factors appear to play a role in arrhythmogenesis, but that their relevance becomes less as VF risk becomes greater owing to 'optimization' of arrhythmogenic conditions, for example, as a consequence of the IZ size being large (Curtis, 1998; Curtis et al., 1993) . Arrhythmogenesis is complex, and there is mediator redundancy, known as 'pathophysiological reserve' whereby numerous factors may be sufficient for arrhythmogenesis; this means that each individual factor will not be necessary for arrhythmogenesis under all conditions (Curtis, 1998; Curtis et al., 1993) . This is nuanced, but the nuance is important, and addressing it distinguishes our objectives from the more simplistic and fallacious concept of catecholamines 'causing' ischaemia-induced VF.
Experimental protocols
Throughout each experimental protocol, a range of ancillary variables, including HR, coronary flow, PR and QT interval at 90% repolarization (QT 90 ), were recorded every 5 min, and the occurrence of ventricular arrhythmias was noted in each 5 min time interval. The QT 90 is recorded in rat studies because the T wave is not distinct and the QRST is a single complex that returns to isoelectric asymptotically, rendering the conventional QT interval (at 100% repolarization) very difficult to measure accurately; use of QT 90 is validated and long established (Rees and Curtis, 1993; ). An arrhythmia score was assigned to each heart for ischaemia and (separately) for reperfusion in order to permit parametric statistical analysis. All these assessments were as described previously (Wilder et al., 2016) .
Hearts were perfused initially with Krebs for 5 min and excluded if predetermined criteria were not met (Wilder et al., 
Figure 1
The five types of ventricular arrhythmias occurring during ischaemia and reperfusion in Langendorff-perfused rat hearts, as defined by the Lambeth Conventions II . VPB, ventricular premature beat; BG, bigeminy. 2016). In total, 38 hearts were excluded, and these were immediately replaced to maintain group sizes whilst maintaining the randomization (see below). Baseline recordings were then made, followed by switch to test solution that varied according to study subset. In the initial study to examine the effects of catecholamines on VF in hearts with different predetermined IZ sizes, these were vehicle (Krebs +50 μM ascorbate) or catecholamine mixture [CAT: 313 nM noradrenaline (NA) and 75 nM adrenaline + 50 μM ascorbate]. In subsequent studies to identify adrenoceptor antagonists with no non-specific off-target pharmacology (in hearts perfused without CATs), these were vehicle (Krebs), 1 or 10 μM atenolol, butoxamine, prazosin, terazosin or trimazosin. In studies to identify the receptor mechanisms involved in mediating CAT effects on VF, these were vehicle (Krebs +50 μM ascorbate), CATs or CATs +1 μM atenolol, butoxamine or trimazosin. The experimental details for these groups are shown in Figure 2 . The CATs mixture used restores HR in Langendorff-perfused hearts to rates seen in conscious rats (Curtis et al., 1985) , and the concentration ratio of NA to adrenaline is representative of the ratio encountered in human plasma (Baumgartner et al., 1985; Goldstein et al., 2003) , especially under conditions of stress (Coplan et al., 1989; Ratge et al., 1986) . We have explained the basis for the CATs mixture more fully and characterized and validated its use in a previous study focused on the role of CATs in mediating VF during infarct evolution (which occurs after periods of ischaemia of more sustained duration than necessary to evoke so-called phase 1 arrhythmias, which are the focus of the present study) (Clements-Jewery et al., 2009) . Ten minutes after solution switch/initiation of pacing, the coronary ligature was tightened to induce regional ischaemia, which was maintained for 30 min and terminated by reperfusion. Although not the main focus of the present study, this allowed examination of CAT effects (in hearts perfused with CATs) on reperfusion-induced VF, with further monitoring of ancillary variables for 10 min (Figure 2 ). Of each group in the pacing study, 50% of hearts were reperfused to enable future sub-analysis of cardiac biochemistry between timematched reperfused and ischaemic tissue, using snap frozen samples (À80°C). Hearts in the catecholamines + antagonist study were not reperfused because IZs and UZs (dissected and frozen in liquid nitrogen) were required for later immunoblot analysis.
Supraventricular pacing
In order to establish or rule out whether CATs facilitate ischaemia-induced VF via effects on HR, a separate group of Krebs' perfused hearts (Figure 1 ) was paced via the right atrium at a rate to match that of the average pre-ischaemia rate caused by CAT perfusion (found to be 405 beats min À1 ) using a silver wire bipolar electrode, connected to a stimulator (CD-S103, Cudos, UK). The stimulator was linked to a PowerLab ™ system (PowerLab 4/35 and Animal Bio Amp, ADInstruments, UK; sampling rate 1 kHz), and hearts were stimulated with square wave pulses at double the threshold pulse width (0.34 ± 0.05 ms duration) and double the threshold voltage (1.75 ± 0.2 V) at 6.75 Hz. Regional ischaemia was induced as described above, to generate small IZs, allowing scope for examining whether sinus tachycardia matching that evoked by CATs was sufficient to increase the incidence of ischaemia-induced VF.
Low-flow global ischaemia
With regional ischaemia in the rat isolated heart, there is limited scope for delivery of exogenous CATs to the IZ owing to the uniform low level of coronary collaterals that delivers a flow to the IZ that is no more than 5% of flow in the UZ (Curtis, 1998) . This means that the aforementioned regional ischaemia studies allow testing only of whether CATs acting in the perfused UZ facilitate ischaemia-induced VF. Therefore, to test the possibility that, with a more substantial level of collateral flow, CATs may additionally act in the IZ to facilitate ischaemia-induced VF, required a different model. We therefore elaborated a low-flow global ischaemia model in which the IZ is continuously perfused to allow CAT delivery. Importantly, any facilitation of ischaemia-induced VF by CATs in a low-flow global ischaemia model can occur only by actions mediated in the IZ (there is no UZ).
Hearts were dissected and cannulated, and an ECG lead positioned as described above. Following 15 min of baseline perfusion with Krebs, the perfusate was switched to test solution and coronary flow was reduced to one of three set levels for 60 min: severe (0.8 mL·min À1 ), moderate (2 mL·min À1 ) or mild (4 mL·min À1 ) low-flow global ischaemia using fixed resistance (clamps) to regulate inflow to the cannula ( Figure 2 ). A group of time-matched regionally ischaemic hearts with large IZs was included in the study to act as a positive control for comparative purposes ( Figure 2 ). Hearts were perfused with vehicle (Krebs +50 μM ascorbate) or CATs. HR, coronary flow, RR and QT 90 interval, ventricular arrhythmias, and heart temperature were recorded at 5 min intervals throughout the protocol. The duration of ischaemia was extended beyond the 30 min sufficient to allow evaluation of phase 1 arrhythmias in the regionally ischaemic heart in order to provide a characterization of the arrhythmia profile, since this rat Langendorff low-flow global ischaemia model is new and uncharacterized. Thus, the experiment was terminated after 60 min of ischaemia.
Adrenoceptor antagonist specificity and selectivity and use of tissue bath myography
Selection of adrenoceptor antagonist concentrations was guided by published IC 50 values, but in order to be sure that the chosen agents possessed specificity (effects attributable to an action on the intended adrenoceptor) and selectivity (effects attributable only to an action on the intended adrenoceptor), a dual approach was taken. Specificity was identified in two ways: (i) from adrenoceptor effects on wellestablished CAT responses in perfused hearts (e.g. inhibition of CAT-induced sinus tachycardia denoting β 1 antagonism); and (ii) from separate blood vessel bioassay studies. For the latter, concentration-response curves (CRCs) were constructed using isolated rat thoracic aortae and tissue bath myography (Myobath II 4-channel tissue bath, WPI, UK). Thoracic aortae were dissected from anaesthetized male Wistar rats (Harlan UK; 350-400 g) and immediately immersed in cold Krebs-Ringer solution, containing NaCl 118 mM, CaCl 2 2H 2 O 2.5 mM, glucose D (+) 11.1 mM, NaHCO 3 25 mM, MgSO 4 1.2 mM, KH 2 PO 4 1.2 mM and KCl 4.8 mM, cleared of perivascular connective and adipose tissue and cut into 4 × 3 mm length rings using five scalpel blades mounted together (equidistance apart). Aortic rings were denuded (endothelium removed) for α 1 -adrenoceptor antagonist experiments in order to preclude β-adrenoceptor agonism-induced NO-mediated vasodilatation (Brawley et al., 2000) . An adapted 21-gauge needle was inserted into the vessel rings and rolled gently against the dissecting dish 10 to 15 times in order to remove endothelia. Aortic rings were mounted and secured via a pair of intraluminal steel wires and submerged in 15 mL tissue baths containing gassed and warmed (95% O 2 : 5% CO 2 ; pH 7.4; 37°C) Krebs-Ringer solution. CRCs were recorded using LabChart v7 software (ADInstruments, UK) and a PowerLab ™
Figure 2
Experimental protocols for varied IZ size study, pacing study, antagonist only studies, catecholamines + antagonist study and low-flow global ischaemia study. CAT (313 nM NA +75 nM adrenaline).
system (PowerLab 4/25 and Pod Expander, ADInstruments, UK; sampling rate 100 Hz).
After a warm-up period of 60 min, during which time baseline vascular tension was set, vascular function was tested (achievement of a vasoconstriction to 60 mM KCl within two SDs from the study mean). Endothelium integrity was then assessed by pre-constricting with 1 μM phenylephrine, with a reversal of >70% of the phenylephrine-induced tone by 10 μM ACh taken to indicate the presence of intact endothelium (β-adrenoceptor constriction experiments) and a reduction of <20% taken to indicate the absence of endothelium (denuded vessels; α-adrenoceptor relaxation experiments). Each bath was subsequently washed out three times with Krebs-Ringer solution and left for 15 min for tension to return to baseline. Vehicle (water), 1 or 10 μM adrenoceptor antagonist (atenolol, butoxamine or trimazosin, volume-matched to vehicle) was added to each tissue bath and left to incubate for 30 min. In β-adrenoceptor CRC experiments, aortic rings were pre-constricted with 1 μM phenylephrine, and the response left to plateau (approximately 15 min). The phenylephrine equilibrium constriction was defined as the tension immediately before the start of the agonist CRC and was normalized to zero. Subsequently, cumulative β-adrenoceptor agonist CRCs were constructed by sequentially increasing the agonist concentration by 0.5 log units [dobutamine (β 1 -adrenoceptor) or salbutamol (β 2 -adrenoceptor); 30 nM to 1 mM] in each tissue bath. Vessels were exposed to each concentration of agonist for 6 min before the next addition. In α-adrenoceptor CRC experiments in which aortic rings were not pre-constricted, α-adrenoceptor agonist CRCs were constructed by sequentially increasing the concentration of phenylephrine by 0.5 log units (30 nM to 1 mM). Vessels were exposed to each concentration of phenylephrine for 2 min (30 nM to 100 μM) or 5 min (300 μM and 1 mM) before the next addition.
Selectivity was established by a two-step process that tested an adrenoceptor concentration that possessed specificity for a lack of non-selectivity. Here, non-selectivity is defined as the ability to inhibit ischaemia-induced VF in the absence of exogenous CATS. The complete strategy is as follows. When a concentration was shown to obtain expected evidence of specificity based on the drug's conventional description (i.e. a β 1 antagonist causing inhibition of CAT-induced sinus tachycardia or an α 1 antagonist causing inhibition of CAT-induced vascular constriction in myograph studies), we tested this concentration to determine that it had no effect on ischaemia-induced VF in rat hearts perfused without exogenous CATs. To achieve the latter, rat hearts were subjected to coronary ligation by the method described above but with all ligatures located proximally to evoke a large IZ. Any adrenoceptor antagonist shown to reduce ischaemia-induced VF incidence at the chosen concentration was deemed to lack selectivity at that concentration, since ischaemia-induced VF in hearts perfused without added CATs is CAT unrelated by definition, and any suppression of such VF cannot be attributed to adrenoceptor antagonism. Several concentrations of adrenoceptor antagonist were tested in separate hearts to determine the threshold concentration for any such loss of selectivity, defined from the no effect levels (NOELs) on VF incidence.
Only adrenoceptor antagonists at concentrations showing sufficient evidence of specificity and selectivity were chosen for subsequent studies to test for inhibition of facilitation of ischaemia-induced VF by CATs in hearts with smaller IZs, using the technique and methods outlined above.
Immunoblotting
To provide further evidence that the adrenoceptors chosen for study possessed the necessary specificity and selectivity, we probed for downstream signal indicative of adrenoceptor agonism. For reasons explained in Results, it was necessary to probe only for β 1 and β 2 signal. Frozen UZs and IZs from the catecholamines + antagonist study (n = 5 per group, hearts chosen at random) were ground to a fine powder and homogenized in EDTA-free lysis buffer. Protein concentration in lysates was determined by performing the Bradford protein assay (Bradford, 1976) . Following the addition of sample buffer (Ehler et al., 1999) , samples were heatdenatured at 95°C for 5 min and subjected to SDS-PAGE [10% acrylamide for cardiac troponin I (cTnI), or 6% acrylamide for ryanodine receptor type 2 (RyR2)]. Proteins were subsequently transferred to PVDF membranes by electrophoretic transfer using a semi-dry (cTnI) or wet transfer (RyR2) method. For immunoblot analysis of proteins, membranes were blocked in 10% (w . v -1 ) non-fat skimmed milk (Marvel, Premier Foods, UK) in TBST for 1 h at room temperature, except for membranes containing RyR2, which were blocked in 5% (w . v -1 ) BSA in TBST for 1 h. Membranes were incubated with primary antibodies overnight at 4°C and were subsequently incubated with secondary antibodies for 2 h at room temperature. Protein bands were detected with ECL Western Blotting Detection Reagents (GE Healthcare, UK). Films were developed in a Fuji X-ray film processor (RGII, Fuji), and protein band density was determined by Quantity One 1D analysis software (Bio-Rad, UK) using a GS-800 Calibrated Densitometer (Bio-Rad, UK).
Data and statistical analysis
The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015) . Group sizes were selected on the basis of expected control incidence of VF and the feasibility of detecting an effect at P < 0.05, using a published design strategy that allows for data sub analysis to ensure that group sizes are not extended to the chosen maximum (n = 20 per group) if there is no scope for an effect approaching statistical significance (Andrag and Curtis, 2013) . Gaussian-distributed variables were subjected to t-tests (where appropriate -two groups, one time point) or ANOVA (one way or two way with repeated measures where applicable), followed by Dunnett's, Tukey's or Sidak's post hoc tests (as appropriate) if F was significant, using GraphPad Prism 6 software. Such values were expressed as mean ± SEM. Western blot densitometry values were normalized to the 'sum of the replicates' (Degasperi et al., 2014) to minimize the effect of sources of variation, before being subjected to statistical analysis. Binomially distributed variables (arrhythmia incidence, classified as 'did' or 'did not' occur) were compared using Fisher's exact test. P < 0.05 was defined as statistically significant. Primary antibodies used for Western blotting were obtained from the following suppliers: rabbit polyclonal anticTnI (4002) and rabbit polyclonal anti-p-cTnI Ser23/24 (4004) from Cell Signaling Technology; rabbit polyclonal anti-calsequestrin 2 (Casq2; PA1-913) and mouse monoclonal anti-RyR2 (MA3-925) from Thermo Fisher Scientific; rabbit polyclonal anti-p-RyR2 Ser2808 (A010-30) from Badrilla; and mouse monoclonal anti-α-actinin (A7732) from Sigma-Aldrich. The secondary antibodies used for Western blotting were obtained from the following suppliers: goat polyclonal anti-rabbit (7074) from Cell Signaling Technology, and goat polyclonal anti-mouse (P0447) from Dako.
Drugs and materials
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology. org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Harding et al., 2018) , and are permanently archived in the Concise Guide to PHARMACOL-OGY 2017/18 (Alexander et al., 2017a,b) .
Results
Catecholamines facilitated ischaemia-induced VF when IZ was small
Varying the location of the coronary ligature obtained the desired IZ sizes, and these were not affected by CATs ( Figure 3A) . Ventricular arrhythmias. CATs increased ischaemia-induced VF incidence but only in hearts with small IZs, in which control VF incidence was low ( Figure 3F ). Other arrhythmias, more prevalent even with small IZs, were not facilitated ( Figure 3B-E) . During reperfusion, the pattern of facilitation was the same with CATs increasing VF incidence in hearts with small IZs from 12 to 56%.
Haemodynamic and ECG changes. CATs increased HR ( Figure 4A , B) and caused PR shortening ( Figure 4C ), as shown previously in perfused rat and mouse hearts (Clements-Jewery et al., 2002; Stables and Curtis, 2009 ). Coronary ligation had no effect on HR ( Figure 4A ) but did lower coronary flow, the extent of which was dependent on IZ size as expected (Curtis, 1998) (Figure 4B ). Reperfusion had no effect on HR ( Figure 4A ) but caused reactive hyperaemia in all groups 1 min after the start of reperfusion (31 min; Figure 4B ).
Coronary ligation transiently shortened QT interval in vehicle controls during the first minute of ischaemia, an effect
Figure 3
IZ sizes resulting from distal, medial or proximal ligation of the left coronary artery (A) and incidence (% of group) of increasingly severe ventricular arrhythmias (VPB to VF) during 30 min of regional ischaemia (B-F) in hearts with small, medium and large IZs (varied IZ size study). n = 20 per group; mean ± SEM (A) or incidence (B-F); *P < 0.05. VPB, ventricular premature beat; BG, bigeminy. CAT (313 nM NA +75 nM adrenaline).
that had resolved by 5 min of ischaemia and was prevented by perfusion with CATs ( Figure 4D ).
Pacing to mimic effects of catecholamines on HR did not facilitate VF
Pacing at 405 beats min À1 maintained HR throughout the experimental protocol (e.g. vs. 259 ± 10 beats min À1 in nonpaced hearts 10 min after the onset of ischaemia, P < 0.05). However, pacing did not increase the incidence of any type of ischaemia-induced arrhythmia ( Figure 5A-D) . IZ sizes were similar between non-paced (10.5 ± 0.9% TVW) and paced hearts (10.3 ± 0.8% TVW) as intended and expected.
Identification of adrenoceptor antagonist concentrations lacking off-target pharmacology
In hearts with large IZs and no added CATs, the α 1 -adrenoceptor antagonists, prazosin and terazosin, significantly reduced ischaemia-induced VF incidence: prazosin from 67% (vehicle) to 17% (1 μM) and 8% (10 μM), and terazosin from 58% (vehicle) to 8% (10 μM). Additionally, prazosin and terazosin reduced HR and coronary flow, and prazosin also affected ECG intervals ( Figure 6 ). All these effects are indicative of adrenoceptor-independent off-target actions (Clements-Jewery et al., 2002; Grimm Jr and Flack, 2011; Thandroyen et al., 1983) , the nature of which are not relevant to the present study, but which rendered these drugs unsuitable as selective probes for the α 1 -adrenoceptor.
Further perfusions with an alternative α 1 -adrenoceptor antagonist, trimazosin, were therefore undertaken. In hearts with large IZs and no added CATs, at 1 μM, neither trimazosin nor the adrenoceptor antagonists atenolol (β 1 ) or butoxamine (β 2 ) affected ischaemia-induced VF (trimazosin: 67 vs. 67% with vehicle; atenolol: 42 vs. 50% with vehicle; butoxamine: 33 vs. 56% with vehicle). In addition, none of these antagonists had any significant effects on ECG intervals (Appendix Figures A1, A2 and A3 A-D) . At 10 μM, however, butoxamine and trimazosin reduced VF incidence to 0 and 25% respectively. Thus, the off-target NOELs for atenolol, butoxamine and trimazosin were 1 μM for each drug.
Identification of adrenoceptor antagonist concentrations with specificity for the intended adrenoceptor
At 1 μM, neither butoxamine nor atenolol had any significant effect on the dobutamine CRC (Àlog EC 50 or maximum response; Figure 7A , B). Butoxamine shifted the salbutamol CRC to the right in a concentration-dependent manner, with the change in -log EC 50 reaching significance at 10 μM ( Figure 7C, D) . Atenolol had no significant effect on the salbutamol CRC ( Figure 7C ) or -log EC 50 ( Figure 7D ). Neither butoxamine nor atenolol affected the maximum relaxation response to salbutamol ( Figure 7D ). Trimazosin caused a concentration-dependent shift to the right of the phenylephrine CRC ( Figure 7E ) and a significant change in the -log EC 50 ( Figure 7F ) without affecting the phenylephrine maximum response ( Figure 7F) . Thus, at 1 μM, a lack of off-target adrenoceptormediated effects was confirmed for all three drugs, and the required on-target adrenoceptor specificity was confirmed for butoxamine and trimazosin. As a result, butoxamine and trimazosin, each at 1 μM, were subsequently used in the 'catecholamine + antagonist' study in order to identify the adrenoceptor(s) mediating the facilitation of ischaemia-induced VF by CATs in hearts with small IZs. The same concentration of atenolol was also taken forward.
Identification of adrenoceptor(s) mediating facilitation of ischaemia-induced VF by CATs
The initial finding that CATs increased ischaemia-induced VF incidence in hearts with small IZs was reproduced in separate hearts ( Figure 8F ). Co-perfusion of CATs with either 1 μM atenolol (β 1 selective) or butoxamine (β 2 selective) inhibited this facilitation, whereas 1 μM trimazosin (α 1 selective) had no effect ( Figure 8F ). This indicates that when CATs facilitate ischaemia-induced VF, this required both β 1 and β 2 agonism. VT facilitation was also significantly reduced by 1 μM butoxamine, whilst 1 μM atenolol reduced VT facilitation as a non-significant trend ( Figure 8E ). The incidences of less severe arrhythmias were unaffected ( Figure 8B-D) . IZ size did not vary between perfusion groups ( Figure 8A) , the means of which were between 20 and 30% TVW as intended. Likewise, TVW was similar in each group (vehicle: 0.92 ± 0.01 g, CATs: 0.95 ± 0.02 g, CATs + atenolol: 0.89 ± 0.02 g, CATs + butoxamine: 0.95 ± 0.02 g, CATs + trimazosin: 0.93 ± 0.02 g).
Haemodynamic and ECG changes. Atenolol (1 μM) reduced the CAT-induced increase in HR; butoxamine (1 μM) had a weaker effect; and trimazosin (1 μM) had no effect ( Figure 9A ). CAT-induced increases in coronary flow followed a similar pattern ( Figure 9B ). Coronary ligation significantly reduced coronary flow in all groups ( Figure 9B ). None of the antagonists prevented the sustained PR shortening or QT prolongation caused by CATs ( Figure 9C 
Independent verification of β-adrenoceptorspecific agonism and β-adrenoceptor-selective antagonism
Protein phosphorylation in the UZ. CATs increased cTnI phosphorylation at Ser23/24, a downstream target of β 1 -adrenoceptor signalling (Puhl et al., 2016) , in the UZ.
Figure 5
Incidence (% of group) of increasingly severe ventricular arrhythmias (VPB to VT) during 30 min of regional ischaemia and 1 min of reperfusion in hearts with small IZs, with or without left atrial pacing (pacing study). n = 12 per group (ischaemia) or 6 per group (reperfusion). N.B. the incidence of ischaemia-and reperfusion-induced VF was zero in both groups. VPB, ventricular premature beat; BG, bigeminy.
Figure 6
Haemodynamic and ECG changes in hearts with large IZs perfused with 1 or 10 μM prazosin (A-D), and 1 or 10 μM terazosin (E-H). HR (A + E), coronary flow (B + F), PR (C + G) and QT intervals (D + H). n = 12 per group; mean ± SEM; *P < 0.05 versus time-matched vehicle. PR, PR interval; QT, QT 90 interval.
This was prevented by 1 μM atenolol but unaffected by 1 μM butoxamine or 1 μM trimazosin ( Figure 10A, B) .
Western blots of the RyR2 revealed two bands (Figure 10  D, H) , corresponding to full length RyR2 (565 kDa) and the c-terminal fragment (~400 kDa) (Li et al., 2013) . The full length RyR2 protein was analysed. Phosphorylation of the RyR2 at Ser2808, a downstream target of β 2 -adrenoceptor-mediated Gα i signalling that inhibits β 1 -adrenoceptor-mediated RyR2 phosphorylation (Schmid et al., 2015) , was increased in the UZ by 1 μM butoxamine ( Figure 10C, D) .
Protein phosphorylation in the IZ. In contrast to UZ data, β 1 -adrenoceptor signalling was evident in the IZs of vehicle controls, but although CATs tended to increase this and atenolol blocked the increase, these trends did not reach significance ( Figure 10E, F) . Again, in contrast to UZ data,
Figure 7
Dobutamine (A), salbutamol (C) and phenylephrine (E) CRCs in the presence of vehicle, 1 or 10 μM atenolol, butoxamine or trimazosin, and -log EC 50 s and maximum response values (B, D, F) derived from the CRCs. n = 5 per group; mean ± SEMs; *P < 0.05. β 2 -adrenoceptor signalling in the IZ appeared to be unaltered by butoxamine (Figure 10G-H) .
Test for IZ-mediated facilitation of ischaemia-induced VF using a low-flow global ischaemia model
The method successfully achieved complete separation and regulation of flow values between low-flow groups ('severe': 0.8 mL·min À1 ; 'moderate': 2 mL·min À1 ; 'mild': 4 mL·min À1 ), as was intended ( Figure 11C ). Low-flow global ischaemia caused sinus bradycardia, and this effect was not surmounted by CATs ( Figure 11D ); although in a concurrent set of hearts with regional ischaemia (large IZs), CATs increased coronary flow and evoked sinus tachycardia ( Figure 11C, D) , as expected. Heart mean temperature fell during ischaemia by no more than 1°C ( Figure 11B ). Low-flow global ischaemia evoked arrhythmias ( Figure 11E ). CATs weakly facilitated ischaemia-induced arrhythmias but only when flow reduction was 'moderate' and importantly only late after ischaemia onset (≥50 min) and not during the phase 1 period characteristic of regionally ischaemic hearts; moreover, the effect obtained statistical significance only for arrhythmia score ( Figure 11F ). QT interval was prolonged by catecholamines but only in the 'moderate' flow reduction group ( Figure 11F, G) .
Discussion
Overview
Published studies do not provide a clear description of the relationship between CATs, derived from the circulation or released by cardiac sympathetic innervation, and ischaemiarelated arrhythmogenesis, with some findings indicative of a link (Meredith et al., 1991; Slavikova et al., 2007) and others indicative of no link (Botting et al., 1983; Curtis et al., 1985; Daugherty et al., 1986; Paletta et al., 1989) . The rat Langendorff preparation is devoid of autonomic nervous reflex or circulating CATs, yet ischaemia-or reperfusioninduced VF normally occurs in almost every heart when the IZ is large, meaning that CATs are not necessary mediators of ischaemia-induced VF Wilder et al., 2016) . The aims of this study were therefore (i) to examine the hypothesis that CATs facilitate (rather than mediate) ventricular arrhythmias caused by acute myocardial ischaemia and (ii) to identify the adrenoceptors involved. When IZ was made small, ischaemia-induced VF was found to be facilitated by a mixture of CATs that mimics the cardiac effects of sympathetic tone by restoring HR to levels seen in rats in vivo (Curtis et al., 1985) and reducing PR interval, as found previously (Clements-Jewery et al., 2002) . VF facilitation was not detectable with larger IZs. Facilitation was inhibited by atenolol (β 1 ) and butoxamine (β 2 ) but not trimazosin (α 1 ), with haemodynamic, Western blot and ancillary vascular bioassay data confirming antagonist specificity and selectivity at the concentrations used. The findings show that, when there is scope, exogenous CATs can increase the risk of ischaemia-induced VF. Scope requires the intrinsic risk of VF to be low relative to that occurring with, for example, a large IZ of 40% or more of ventricular mass. These data, and the findings from hearts subjected to lowflow global ischaemia (no VF facilitation during the 'phase 1' period of early ischaemia), indicate an action mediated primarily if not exclusively in the UZ. The antagonist data revealed the effects to be to β 1 -and β 2 -adrenoceptor-mediated, confirmed by Western blotting, with activation of both receptors necessary for facilitation.
Figure 8
IZ size (A) and incidence of increasingly severe ventricular arrhythmias (VPB to VF; B-D) during 30 min of regional ischaemia in hearts with small IZs, perfused with vehicle, CATs or CATs +1 μM atenolol, butoxamine or trimazosin. n = 20 per group; mean ± SEM (A) or incidence (B-F); *P < 0.05. VPB, ventricular premature beat; BG, bigeminy. CAT (313 nM NA +75 nM adrenaline).
Role of alterations in HR, coronary flow and QT in mediating the facilitation of VF
In rat isolated hearts with large IZs (~40% TVW), there is a relationship between HR and ischaemia-induced VF, but this becomes evident only at HRs in the sinus tachycardia range (e.g. 480 beats min À1 ) (Bernier et al., 1989) . In dogs in vivo, likewise, variation in HR over the normal range for the species (i.e. 150-200 beats min À1 ) had little effect on ischaemiainduced VF risk (Bolli et al., 1986) . In the present study, in hearts paced to match the HR of CAT-perfused hearts (405 beats min À1 ), there was no increase in ischaemia-induced VF incidence, meaning that VF facilitation by CATs was not secondary to sinus tachycardia. CAT perfusion increased QT interval in the catecholamines + antagonist study ( Figure 8D ), as found previously (Clements-Jewery et al., 2002; Clements-Jewery et al., 2006) . In previous studies, CATs were introduced 90 min after the onset of regional ischaemia to hearts that had, by this time, recovered sinus rhythm following the paroxysms of early (phase 1) arrhythmias (Clements-Jewery et al., 2002) . At this time, rat hearts are susceptible to developing phase 2 arrhythmias, which manifest primarily by non-re-entrant mechanisms (Clements-Jewery et al., 2009) , different from the flow of injury current and re-entry that operate during the first 30 min of ischaemia (phase 1) (Sidorov et al., 2011) . CAT perfusion failed to facilitate phase 2 arrhythmias (Clements-Jewery et al., 2002; Clements-Jewery et al., 2006) , despite the fact that the (predominantly non-re-entrant) mechanisms of phase 2 are supposedly highly susceptible to facilitation by CATs (Antzelevitch and Burashnikov, 2011) . If the QT prolongation observed in the present study was to have had any effect on the re-entrant mechanisms occurring during phase 1, suppression of VF rather than facilitation would be the expected outcome (Nattel, 2008) . Thus, it is not tenable that the observed QT prolongation contributed to the facilitation of ischaemia-induced VF by CATs. It should be noted that the lack of identifiable QT interval prolongation by CATs in the varied IZ size study ( Figure 3D ) was likely due to differences in baseline (pre-ischaemia/pre-switch) QT interval compared to baseline QT interval in the catecholamines + antagonist study ( Figure 8D ), meaning that there was reduced scope for detection of CAT-induced prolongation. In both studies, QT interval was approximately 80 ms after switching to CATs.
Figure 9
Haemodynamic and ECG changes in hearts with small IZs perfused with vehicle, CATs or CATs +1 μM atenolol, butoxamine or trimazosin. (A) HR, (B) coronary flow, (C) PR and (D) QT intervals. n = 20 per group; mean ± SEM; P < 0.05 indicated in the figure. PR, PR interval; QT, QT 90 interval. CAT (313 nM NA +75 nM adrenaline).
Figure 10
Quantification of UZ (A-D) and IZ (E-H). Western blots probed for total cTnI and p-cTnI (A, B; E, F), and total RyR2 and p-RyR2 (C, D; G, H). n = 5 per group; mean ± SEM; *P < 0.05. p-cTnI, phosphorylated cardiac troponin I; Casq2, calsequestrin 2 (cardiac); p-RyR2, phosphorylated RyR2 (cardiac). CAT (313 nM NA +75 nM adrenaline).
Evidence of drug selectivity and specificity for adrenoceptor identification
In order to identify the adrenoceptors mediating the CAT effects, it was necessary to select concentrations of adrenoceptor antagonists that exhibited selectivity and specificity. Specificity was established from rat aorta myography experiments and/or from evidence of antagonism of haemodynamic and intracellular signalling effects of CATs in perfused hearts. Selectivity was established from a lack of actions indicative of non-selectivity, in particular, a lack of effect on ischaemia-induced VF in hearts perfused without added CATs.
Prazosin and terazosin both failed to meet specificity/selectivity requirements. The mechanism of their 'off target' effects is irrelevant in the present context, albeit prazosin certainly possesses Na + channel blocking activity (Daugherty et al., 1986; Thandroyen et al., 1983) . In contrast, atenolol, butoxamine and trimazosin met the selectivity requirements at 1 μM. This does not necessarily mean that these antagonists do not have any adrenoceptorindependent actions at 1 μM, but it shows that any such actions do not affect any of the haemodynamic and ECG variables measured or inhibit ischaemia-induced arrhythmias in the absence of exogenous CATs. Furthermore, 1 μM of these drugs also possessed the required adrenoceptor specificity, judged from ancillary whole heart pharmacology (e.g. effects on HR), ancillary rat aorta myography experiments and/or Western blotting. The myography showed that 1 μM butoxamine and 1 μM trimazosin had the necessary specificity for β 2 -or α 1 -adrenoceptors. The specificity of atenolol for
Figure 11
IZ size in hearts with large IZs (A), heart temperature (B), coronary flow (C), HR (D), mean 5-point arrhythmia score in hearts perfused without CATs (E), 5-point arrhythmia score from hearts with 'moderate' (2 mL·min À1 ) low-flow global ischaemia (F), and QT interval at 60 min of ischaemia (G) in hearts with low-flow global ischaemia or large IZs, perfused with vehicle or CATs. n = 12 per group; mean ± SEM; †P < 0.05 versus timematched large IZ vehicle control; *P < 0.05. QT, QT 90 interval. CAT (313 nM NA +75 nM adrenaline).
the β 1 -adrenoceptor, however, could not be established from the aorta assay. This was unanticipated, but we found after completing studies that the rat thoracic aortae has a low expression of β 1 -adrenoceptors (Perez-Aso et al., 2014) . Specificity of atenolol for the β 1 -adrenoceptor was nevertheless established independently from its ability to antagonize the increase in HR caused by CATs ( Figure 9A ) and from the abolition of the CAT-stimulated β 1 -adrenoceptor signal (p-cTnI/ cTnI; Figure 10A ). The array of effects on multiple variables therefore confirmed the specificity and selectivity of 1 μM of butoxamine, trimazosin and atenolol, establishing their validity as pharmacological tools in the present context.
Facilitation of ischaemia-induced VF via actions in the IZ
Collateral flow in the rat IZ is <5% normal flow (Maxwell et al., 1987) , and the ischaemic milieu in the rat heart is effectively stagnant and not conducive to delivery and accumulation of labile substances such as CATs. However, should sufficient amounts of CATs be able to access the IZ during early ischaemia, as may occur in well-collateralized hearts of some species other than rat, adrenoceptor activation in the IZ may be sufficient to facilitate ischaemia-induced arrhythmias. To test this, a low-flow global ischaemia model was used, in which the site of action of perfused CATs is, unavoidably and exclusively, the IZ, and residual flow can be controlled precisely. CATs did facilitate ischaemia-induced arrhythmias in these hearts, but effects were weak, detectable only by using an arrhythmia score that (unlike VF incidence) permits use of powerful parametric statistics, and required a prolonged period of ischaemia to become apparent (well beyond the window of phase 1 arrhythmias associated with regional ischaemia) (Curtis, 1998) . Furthermore facilitation occurred only when coronary flow was reduced 'moderately' to 2 mL·min À1 and not when flow reduction was mild or severe, consistent with a need for residual flow to be sufficiently high to deliver CATs swiftly enough to preclude the perfused tissue degrading them, yet sufficiently low to cause ischaemia of necessary severity to generate an arrhythmogenic substrate. Overall, the weak facilitation of ischaemia-induced VF by CATs acting within the IZ was insufficient, and far too delayed, to have contributed meaningfully to the facilitation of VF observed during regional ischaemia. There is evidence that endogenous NA may accumulate in the ischaemic region owing to local acidity driving uptake 1 in the reverse mode in the surviving sympathetic afferents and that this occurs even in rat isolated hearts in which the postganglionic sympathetic afferents are unavoidably detached from the CNS (Schömig et al., 1984) . However, this process is unlikely to have contributed to any of the present study outcomes. There are several reasons for this.
The first is that the key variable we examined was the increase in VF incidence caused by perfusion with catecholamines delivered to the uninvolved non-ischaemic region. It is difficult to conceptualize how uptake 1 in the reverse mode in the ischaemic region could be increased by perfusing the uninvolved region with catecholamines or how this, if it occurs, would account for the increase in ischaemia-induced VF caused by perfusion with catecholamines. To examine the receptor mechanism, we used adrenoceptor antagonists shown to have no action on ischaemia-induced VF in hearts perfused without added catecholamines (meaning these drugs had no effect on the actions of any endogenous NA released via uptake 1 in the reverse mode during ischaemia). Likewise, it is not possible to explain inhibition of the increase in ischaemiainduced VF caused by perfusion with catecholamines by the two β-adrenoceptor antagonists (butoxamine and atenolol at 1 μM) on the basis of a supposed inhibition of the actions of endogenous NA in the ischaemic region (released by uptake 1 in the reverse mode) because these drugs at the concentration used (1 μM) had no effect on ischaemia-induced VF incidence in hearts perfused without added catecholamines.
Whether or not NA released by uptake 1 in the reverse mode can contribute to ischaemia-induced VF in a wider sense is a separate issue that may warrant separate investigation. In view of possible reader interest in the topic, we have expanded on the role of uptake 1 in ischaemiainduced VF below.
Interestingly, the data derived by Schömig et al. (1984) do not show that uptake 1 in the reverse mode operates during ischaemia. Schömig et al. (1984) measured NA release during reperfusion. Other investigators have made similar measurements, again during reperfusion (Wilde et al., 1988) . One of the few papers that measured NA within ischaemic tissue itself found a reduction in tissue NA content in a rat in vivo model after 20 and 30 min of ischaemia (earlier time points not examined) (Abrahamsson et al., 1981) . The latter study refers to the conflicting evidence for changes in tissue NA during ischaemia. There is evidence that NA accumulates in the interstitial fluid in the ischaemic myocardium from work by Lameris et al. (2000) using microdialysis probes implanted into the left ventricle of pigs. But just as in the case of Schomig's rat heart data (Schömig et al., 1984) , the time course of accumulation shows a large disparity with the known temporal pattern of VF during ischaemia; interstitial NA was still rising 60 min after the onset of ischaemia, long after the phase 1 arrhythmia period is over in pigs, whilst values at the peak of arrhythmia incidence were relatively low (Lameris et al., 2000) .
Species differences, or experimental setting, may also be an issue. The study by Lameris et al. (2000) shows that ischaemia causes release of NA in pigs in vivo. However, as noted above, the evidence for this in isolated denervated rat hearts is less persuasive. Indeed, Daugherty et al. (1986) found that during continuous regional ischaemia in the rat Langendorff preparation (with no added catecholamines), the low level of collateral flow allowed the release of accumulating lactate to be detected during ischaemia, but there was no commensurate release of NA. This confirms that the release of NA during reperfusion observed by Schömig et al. (1984) in the rat Langendorff was, in part at least, reperfusion-induced, rather than washout of NA that had accumulated during ischaemia.
There is actually very little work that addresses specifically the role of uptake 1 in the reverse mode as an arrhythmogenic mechanism. Few of the published studies measure arrhythmias and NA contiguously. In one of the more recent relevant articles published on the subject, (Du et al., 1998 ) the authors noted, 'We found that depletion of noradrenaline prevented arrhythmias in anoxic hearts but failed to do so in ischemic hearts', and added that 'in noradrenaline-depleted hearts, desipramine and imipramine … remained potent in preventing arrhythmias'. Ischaemia-induced VF can therefore still occur in hearts depleted of catecholamines, and this is inhibited by drugs that inhibit uptake 1, meaning there can be no obligatory or necessary role for uptake 1 in the reverse mode in the mediation of ischaemia-induced VF, and that the drug tools used earlier by Schömig et al. (1984) and others (Kurz et al., 1995; Richardt et al., 2006) evidently lack selectivity for uptake 1.
Overall, these data show that there is no basis for giving serious consideration to the possibility that uptake 1 in the reverse mode has relevance to the present study's findings.
Identification of the adrenoceptors mediating facilitation of VF
Given the selectivity and specificity of 1 μM atenolol and butoxamine, their effects on VF indicates, somewhat unexpectedly, that simultaneous activation of β 1 -and β 2 -adrenoceptors is necessary for VF facilitation by CATs since, if activation of only one or other adrenoceptor were necessary, only one or other of the antagonists would have had the capability to reduce VF incidence.
With respect to mechanism, separate pacing studies showed that VF facilitation was not a secondary consequence of an increase in HR, and inhibition of VF facilitation was not secondary to any inhibition of the increase in HR.
In UZs, atenolol prevented the phosphorylation of cTnI by CATs, indicative of inhibition of β 1 -adrenoceptor signalling (Puhl et al., 2016) , whereas butoxamine and trimazosin had no effect. These data confirmed the evidence outlined above that atenolol inhibited VF facilitation via β 1 antagonism whereas butoxamine inhibited VF facilitation via a β 1 -independent action.
Evidence of suppression of β 2 -adrenoceptor-mediated signalling by butoxamine was sought by probing for RyR2 phosphorylation, a relatively novel and unestablished method that depends upon β 1 -adrenoceptor signalling increasing RyR2 phosphorylation (via Gα s ), whilst β 2 -adrenoceptor signalling attenuates it (via Gα i ) (Schmid et al., 2015) . The, pRyR2 levels in the UZ were increased by CATs + butoxamine versus vehicle-perfused hearts, as anticipated. However, pRyR2 levels were unchanged in the CATs + atenolol group, which would suggest that the RyR2 is phosphorylated additionally by adrenoceptor-independent mechanisms. This would also explain the detectable baseline levels of p-RyR2 in the UZs of vehicle-perfused hearts and the lack of detectable attenuation of p-RyR2 in CAT + atenolol-perfused hearts in the present study. The β 2 -adrenoceptor signalling assessment was therefore disappointing. Nevertheless, the key finding was that butoxamine (but not atenolol) demonstrated specificity at the β 2 -adrenoceptor. Taken together, the present data confirm that butoxamine reduced the facilitation of ischaemia-induced VF by CATs via selective and specific β 2 -adrenoceptor antagonism.
Although we processed IZ tissue, the data were shown for purposes of transparency rather than to explore any hypothesis. The IZ Western blots were more variable than blots from the UZs, as one might expect given that ischaemia as well as CATs can affect adrenoceptor signal expression levels. For example, cTnI phosphorylation at Ser23/24 is elevated during regional ischaemia in murine hearts (Nixon et al., 2014) , and the acidic conditions of ischaemia can increase p-cTnI in rat hearts (Mundina-Weilenmann et al., 1996) .
Nevertheless, atenolol and butoxamine had no effect on β 1 or β 2 signalling in the IZ, consistent with the more compelling evidence discussed above that the facilitation of VF by CATs and its inhibition by atenolol or butoxamine were mediated primarily if not exclusively in the UZ.
Mechanistic insight and limitations of present findings
It was not our objective to explore the electrophysiological mechanisms by which CATs facilitate ischaemia-induced VF. This is partly because it is well known that ischaemiainduced changes in IZ action potential (AP) shape and conduction velocity that generate AP heterogeneity between the IZ and UZ and facilitate arrhythmogenic flow of injury current (Janse et al., 1980; Janse and Wit, 1989 ) are exacerbated by CATs via actions in the UZ (the AP depolarises faster, increasing conduction velocity, and hyperpolarizes to a more negative membrane potential during diastole) (Dorian, 2005; Janse and Wit, 1989) . What was not known, and what formed the focus of this study, was the extent to which these effects of CATs contribute to ischaemia-induced VF. The mechanistic insight provided by the present data concerns the identification of the scope for VF facilitation by CATs (i.e. the potential relevance), the site of action and the identity of the receptor mechanisms responsible (which are targetable by drugs).
As in previous studies (Clements-Jewery et al., 2002; Clements-Jewery et al., 2006) , our method of mimicking sympathetic influence in a preparation that ordinarily has none is a practicable and tractable approach, and one that is validated in terms of achievement of what is intended -restoration of cardiac variables to levels typical of the conscious rat (Clements-Jewery et al., 2002) . However, perfusion with any mix of NA and adrenaline cannot mimic precisely the influence of the sympathetic nervous system on the heart in vivo, which comprises a mix of circulating CATs and noradrenergic neurotransmission, neither of which are ever in true steady state, meaning the possibility of additional VF-facilitating actions secondary to autonomic turbulence. Modelling this may be warranted in future studies.
Conclusion
In rat isolated perfused hearts in which baseline risk of phase 1 ischaemia-induced VF was made deliberately low, exogenous CATs facilitated VF with effects mediated predominantly in the UZ. The facilitation occurred via β 1 and β 2 agonism, with activation of both types of adrenoceptor necessary. These findings may partially explain why, in humans, β blockers (of varying selectivity) have only moderate benefit in reducing mortality and ventricular arrhythmias in patients at risk of acute MI (β-Blocker Heart Attack Study Group, 1981) , since VF risk is likely to be reduced only in patients with smaller IZs. 
Facilitation of ischaemia-induced VF
Relationship between heart weight and VF incidence across all studies All studies were randomised so any relationship between heart weight and VF incidence will have had no influence on differences in VF incidence between groups, or account for any effects seen. TVW vs. ischaemia-induced VF incidence from hearts from all studies used in this paper (30 study data sets) has been plotted (Appendix figure A4) .
There is no correlation between TVW and ischaemia-induced VF incidence according to Pearson correlation calculation. This shows that TVW is not an independent source of error in our studies. Thus, although body weight and heart size varied in the study overall, this was not a significant source of variance with respect to ischaemia-induced VF incidence.
Figure A4
Relationship between TVW and VF incidence from all hearts used in all studies. Mean ± SEM, Pearson correlation calculation.
